Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCO, GAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03632798IIIRecurrent ovarian cancerAvastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMS, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT02584478IIaRecurrent ovarian cancerA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)CA, FL, LA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AnlotinibAL3818, CatequentinibVEGFR2/3 kinase inhibitorClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerFL, NM, OH, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT02873962IIPlatinum resistant or partially sensitive ovarian cancerA Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerCA, MA, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIRecurrent ovarian cancerCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCA, FL, MD, MI, MO, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03579316IIRecurrent ovarian cancer with progression on or after prior PARP inhibitorA Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune responseClinical Trials
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumCA, FL, GA, IL, IN, NJ, NM, OH, OK, PA, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03836352IIRecurrent ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.CA, FL, GA, KY, LA, NM, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivinClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrigatinibAP26113ALK and EGFR kinase inhibitorApproved in Other Cancers
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
2X-121PARP/Tankyrase inhibitor 2X-121, E7449PARP inhibitorClinical Trials
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02710253IIAdvanced solid tumors (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
NCT02819843IIAdvanced solid tumors - intratumoral injectionA Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsNJ, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
Talimogene LaherparepvecGM-CSF-encoding oncolytic herpes simplex virus, T-VECInduces immune response and tumor cell lysisApproved in Other Cancers
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
EntrectinibTrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101ALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
GDC-0084RG7666, PI3K inhibitor GDC-0084PI3K/mTOR inhibitor
NCT03993379IIAdvanced solid tumorsA Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsCA, ID, IL, KY, MA, NY, OR, PA, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CX-072protease-activated anti-PD-L1 antibody prodrug CX-072Blocks PD-L1 inhibition of T cellsClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NCT04003623IIAdvanced solid tumors with FGFR mutations or translocationsA Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)CA, FL, HI, IL, MD, NJ, OH, SD, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PemigatinibINCB054828, FGFR inhibitor INCB054828FGFR1-3 inhibitorClinical Trials
NCT04034927IIPlatinum sensitive high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerCA, CT, GA, IL, MO, NM, NY, OH, OK, PA, RI, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT04083976IIAdvanced solid tumors with FGFR mutations or gene fusionsA Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsCO, CT, FL, GA, IL, ME, MA, MI, NJ, NY, NC, PA, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitorApproved in Other Cancers
NCT04098068IIAdvanced solid tumors with high TMB and low MSIPhase 2 Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) TumorsMD, MA, NY, OH, OR, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04171700IIAdvanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51DA Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair GenesCA, FL, IA, MA, NY, OK, PA, TN, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT04149275IIRecurrent carcinosarcomaCabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic CarcinosarcomaALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CabozantinibCometriq, XL184, Cabometyx, BMS-907351Multi-targeted RTK inhibitorApproved in Ovarian Cancer
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04239014IIRecurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapyA Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance TreatmentContact research study staffView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04042116Ib/IIAdvanced solid tumorsA Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid TumorFL, OK, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03330405Ib/IIPlatinum sensitive recurrent ovarian cancer with mutations in ATM or BRCAA Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid TumorsAR, CA, DC, MA, MI, MN, NY, OH, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitorApproved in Other Cancers
NCT03717415Ib/IIAdvanced solid tumorsAn Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsCA, IL, IN, KS, NC, OH, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitorClinical Trials
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsCA, LA, NY, OH, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Directs costimulation of TILs to HER2+ tumor cellsClinical Trials
NCT02761694IbAdvanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN MutationsOK, SC, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ARQ 751pan-AKT inhibitor ARQ 751Akt inhibitorClinical Trials
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)Approved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCA, CT, FL, IL, NJ, NY, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EpacadostatIDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360Inhibits IDO1 to stimulate immune responseClinical Trials
MGA012INCMGA00012, anti-PD-1 monoclonal antibody MGA012Blocks PD-L1/2 inhibition of T cellsClinical Trials
ParsaclisibPI3K-delta inhibitor INCB050465, INCB050465PI3K delta inhibitorClinical Trials
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairCAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03150810IbAdvanced solid tumors (inc ovarian expansion)A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid TumorsMI, MO, NY, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PamiparibPARP inhibitor BGB-290PARP inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryOKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GalunisertibLY2157299TGFBR1 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03842228IbAdvanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA, POLD1, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (inc expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid TumorsCO, MA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03872947IbPlatinum sensitive or partially sensitive ovarian cancer with no prior gemcitabineA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT03695380IbPlatinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (in expansion)A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerAZ, CA, FL, GA, MD, MO, NY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT04244552IbAdvanced solid tumorsA First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults With Advanced Solid MalignanciesNCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ATRC-101Anti-tumor immune responseClinical Trials
NCT04332653IbAdvanced solid tumorsAn Open-label Phase 1b/2a Study of NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid TumorsContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NT-I7recombinant human IL-7-hybrid Fc NT-I7, Hyleukin, GX-I7IL-7R agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03209401Ia/IbAdvanced solid tumors with mutations in ARID1A, ATM, ATRX, BAP1, BARD1, BLM, BRCA1/2, BRIP1, CHEK1, CHEK2, FAM175A, FANCA/C/D2/E/F/G/L, MLL2, MRE11A, NBN, PALPB2, PTEN, RAD50/51/51B, SLX4, WRN, or XRCC (inc expansion)Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesDC, NJ, NCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT03110107I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsCO, MA, NV, NJ, NY, PA, SDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986218Blocks CTLA-4 inhibition of T cellsClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02754141I/IIaAdvanced solid tumorsA Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsCT, IL, MD, MA, NY, OK, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986179anti-CD73 monoclonal antibody BMS-986179Blocks Ecto-5-nucleotidase (CD73) inhibition of T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02650986I/IIaAdvanced solid tumorsA Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced MalignanciesNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1Clinical Trials
TGFbeta DNRII-transduced Autologous Tumor Infiltrating LymphocytesTGFbeta Dominant Negative Receptor II transduced TILSTGFbeta ligand trap, Anti-tumor immune response enhanced by TGFbeta inhibitionClinical Trials
NCT04219254I/IIaAdvanced solid tumors with prior anti-PD-1/PD-L1 AbA Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Previously Treated With Anti-PD-1 or Anti-PD-L1 AntibodiesCO, MI, MN, OK, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI-1206anti-CD32B monoclonal antibody BI-1206, anti-hFcγRIIB monoclonal antibody BI-1206Blocks CD32B inhibition of immune cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03973333I/IIAdvanced MAGE-A4+ solid tumorsA Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive CancerCA, IL, NY, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IMC-C103CIMC-C103C, a T cell redirecting bi-specific biologicRe-directs T cells to attack MAGE-A4+ tumor cellsClinical Trials
NCT04205227I/IIAdvanced ETBR+ solid tumorsA Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsContact research study staffView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ENB003ETBR antagonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03515551I/IIAdvanced NY-ESO-1+/LAGE-1+ solid tumorsA Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive CancerCO, FL, IA, MI, MO, NY, PA, TN, TX, UTView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IMCnyesoGSK01, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyesoRe-directs T cells to attack NY-ESO-1+/LAGE-1+ tumor cellsClinical Trials
NCT04266912I/IIAdvanced solid tumors with alterations in ARID1A, ATM, ATR, ATRX, BAP1, BARD1, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCM, MRE11A, MSH2, NBN (NBS1), PALB2, RAD51, RAD51C, RAD51D, SMARCB1 or VHLDNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Trial in Patients With Advanced Solid Tumors Harboring Aberrations In DDR Genes (D-BoB)TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
BerzosertibATR kinase inhibitor VX-970, VE-822, M6620, VX-970ATR kinase inhibitorClinical Trials
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
NCT04009681I/IIAdvanced solid tumorsAn Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination With a Checkpoint Inhibitor in Adult Subjects With Advanced or Metastatic Solid TumorsCO, FL, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PD-1iBlocks PD-L1/2 inhibition of T cells
THOR-707pegylated recombinant interleukin-2 THOR-707IL-2 receptor beta and gamma agonistClinical Trials
NCT04317105I/IIAdvanced solid tumors (inc expansion)A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid TumorsContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02111850I/IIAdvanced MAGE-3+ solid tumorsPhase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and AldesleukinMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
Anti-MAGE-A3-DP4 TCR PBLHLA-DP0401/0402-restricted, MAGE-A3-reactive T cell receptor-transduced autologous T cellsImmune response against cancer expressing MAGE-3Clinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT02953457I/IIRecurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or LOH high scoreA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT02671435I/IIAdvanced solid tumorsA Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsAL, AZ, CA, CO, FL, IL, MD, MA, MI, NJ, NY, PA, RI, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Monalizumabanti-NKG2A monoclonal antibody IPH2201, IPH2201Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytesClinical Trials
NCT02432378I/IIPlatinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injectionA Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 VaccinesPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Alpha-DC1 vaccineImmune response against tumor-associated antigensClinical Trials
CelecoxibCelebrexApproved in Other Indications
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT02734004I/IIPlatinum sensitive recurrent ovarian cancerA Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsGA, MD, MA, MI, MO, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitorClinical Trials
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02487095I/IIExtrapulmonary small cell ovarian cancerA Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BerzosertibATR kinase inhibitor VX-970, VE-822, M6620, VX-970ATR kinase inhibitorClinical Trials
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03314935I/IIAdvanced solid tumorsA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsAL, CA, GA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
INCB001158CB-1158, Arginase inhibitorArginase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCO, FL, MD, NJ, NY, OH, OR, PA, SC, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03386526I/IIAdvanced solid tumorsA Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APG-1387SMAC mimetic and IAP antagonistClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03157128I/IIAdvanced solid tumors with RET alterationsA Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibRET kinase inhibitor LOXO-292, LOXO-292RET-kinase inhibitorClinical Trials
NCT03665285I/IIRecurrent ovarian cancerA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsCA, CT, NJ, NY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NC318anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318Blocks tumor-associated macrophage stimulation of tumor growthClinical Trials
NCT03721679I/IIAdvanced solid cancersPoly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot StudyMD, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CemiplimabREGN2810, anti-PD-1 monoclonal antibody REGN2810Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
poly ICLCpoly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizerActivates dendritic cells and induces interferon productionClinical Trials
NCT03761914I/IIRecurrent or persistent WT1+ ovarian cancerA Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced CancersCA, CO, FL, NJ, NY, OH, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Galinpepimut-SSLS 001, WT-1 analog peptide vaccine SLS-001Immune response against cancer expressing WT1Clinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03744468I/IIAdvanced solid tumorsPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsCO, PAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BGB-A425Blocks TIM-3 inhibition of T cellsClinical Trials
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03767348I/IIAdvanced solid tumor - intratumoral injectionAn Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAL, AZ, CA, CT, FL, IA, KY, NJ, NY, OR, TN, TX, UT, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT03840200I/IIRecurrent ovarian cancerA Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate CancerCA, NJ, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03907852I/IIAdvanced mesothelin+ solid tumorsA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing CancerMD, NY, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
TC-210 T cellsTC-210 TruC-T cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03992131I/IIAdvanced solid tumorsSEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid TumorMA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitorClinical Trials
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03994601I/IIAdvanced solid tumorsA Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant TumorsCO, MD, MO, NJView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986288Undisclosed mechanismClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04021043I/IIAdvanced solid tumorsPhase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986156GITR (glucocorticoid-induced TNFR) agonistClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
NCT03997968I/IIAdvanced solid tumorsA Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsCO, FL, NJ, PA, TN, TX, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CYT-0851RAD51 inhibitor
NCT03138083I/IIAdvanced solid tumors with MET alterationsA Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OMO-1JNJ-38877618, MET kinase inhibitor OMO-1c-Met kinase inhibitor
NCT04104776I/IIAdvanced solid tumorsA Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid TumorsMI, NJ, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CPI-0209EZH2 histone methyltransferase inhibitor
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
NCT03785249I/IIAdvanced solid tumors with KRAS G12C mutationsA Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C MutationCA, CO, MA, MI, NY, NC, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MRTX849KRAS G12C inhibitor MRTX849KRAS G12C inhibitorClinical Trials
NCT03729596I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsMI, NC, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MGA012INCMGA00012, anti-PD-1 monoclonal antibody MGA012Blocks PD-L1/2 inhibition of T cellsClinical Trials
MGC018A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payloadADC: anti-B7-H3 + DNA alkylating agent (duocarmycin)Clinical Trials
NCT04068194I/IIAdvanced solid tumorsA Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesCA, NJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
Radiation TherapyRadiotherapy, Irradiation
NCT04143711I/IIAdvanced HER2+ solid tumorsA Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsRI, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DF1001Activates NK cells to stimulate immune response
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03907969I/IIAdvanced solid tumorsA Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced MalignanciesCT, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD7648DNA-PK inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03600883I/IIAdvanced solid tumors with KRAS G12C mutationsA Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)CA, CO, CT, FL, GA, IN, MA, MI, MO, NY, NC, PA, SC, TN, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AMG 510KRAS mutant-targeting AMG 510KRAS G12C inhibitorClinical Trials
NCT03297424I/IIAdvanced solid tumorsA Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced MalignanciesAZ, FL, NY, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PLX2853BRD4 inhibitor PLX2853BRD4 inhibitor
NCT04165330I/IIAdvanced solid tumorsA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid TumorsCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AnlotinibAL3818, CatequentinibVEGFR2/3 kinase inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04165031I/IIAdvanced solid tumors with KRASG12C mutationA Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C MutationCA, IL, IN, MA, NH, NJ, NY, NC, OK, TN, TX, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonistApproved in Other Cancers
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
ErlotinibTarcevaEGFR kinase inhibitor
LY3499446KRAS G12C inhibitor
NCT02660034I/IbPlatinum sensitive or partially sensitive ovarian cancer (at least 2 prior platinum therapies, in expansion)A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid TumorsAZ, CA, FL, MA, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PamiparibPARP inhibitor BGB-290PARP inhibitorClinical Trials
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT01417546IAdvanced solid tumors (in expansion)First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NHS-IL12immunocytokine NHS-IL12, M9241IL-12 receptor agonistClinical Trials
NCT03435250IAdvanced solid tumors with CDKN2A deletion (inc expansion)A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAPCT, MA, NY, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AG-270Methionine adenosyltransferase 2a (MAT2A) inhibitorClinical Trials
NCT03255070IAdvanced HER+ solid tumorsA Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 ExpressionMOView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ARX788anti-HER2 antibody-drug conjugate ARX788, ADC ARX788ADC: anti-HER2 + microtubule destabilizer (MMAF)Clinical Trials
NCT03330561IAdvanced HER2+ solid tumors (inc expansion)A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsAZ, CA, DC, MD, NY, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Directs costimulation of TILs to HER2+ tumor cellsClinical Trials
NCT03059823IAdvanced solid tumors (in expansion)A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid TumorsAZ, MI, NJ, NC, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MGA012INCMGA00012, anti-PD-1 monoclonal antibody MGA012Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT03431948IAdvanced solid tumors (amenable to radiation therapy)Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsILView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyRadiotherapy, Irradiation
UrelumabBMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibodyStimulates 4-1BB (CD137) to increase T cells and immune responseClinical Trials
NCT03335540IAdvanced solid tumorsADaptiVe Biomarker Trial That InformS Evolution of TherapyIL, MD, PAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986205Inhibits IDO1 to stimulate immune responseClinical Trials
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitorClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cellsClinical Trials
NCT03144661IRecurrent ovarian cancerA Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesAL, NY, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INCB062079FGFR4 inhibitorClinical Trials
NCT03154294IAdvanced solid tumorsA Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid TumorsSDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
SapanisertibTAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128TORC1/2 kinase inhibitorClinical Trials
SerabelisibPI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117PI3K alpha inhibitorClinical Trials
NCT03213964IRecurrent advanced ovarian cancer only in abdomen/pelvisIntraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FATE-NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune responseClinical Trials
NCT03724890IAdvanced solid tumorsA Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid TumorsCA, FL, IL, NY, OH, OK, PA, SC, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
Radiation TherapyRadiotherapy, Irradiation
NCT03725436IAdvanced solid tumors that are TP53 WTA Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ALRN-6924MDM2/MDMX inhibitor ALRN-6924MDM2 and MDMX inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03691376IRecurrent or refractory NY-ESO-1+ ovarian cancerA Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
MelphalanSarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustardDNA damaging agentApproved in Other Cancers
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)Immune response against cancer expressing NY-ESO-1Clinical Trials
NY-ESO-1 CD8-TCR Engineered T CellsImmune response against cancer expressing NY-ESO-1Clinical Trials
NCT03502733IAdvanced solid tumors (in expansion)Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and LymphomasMD, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03585764IRecurrent or persistent FRalpha+ high grade serous ovarian cancerPhase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
MOv19-BBz CAR TImmune response against cancer expressing folate receptorClinical Trials
NCT03486301IAdvanced solid tumors (inc expansion)Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsFL, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BDB001TLR agonist and immune cell stimulatorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT01434316IAdvanced solid tumors including those with BRCA1/2 mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DinaciclibCDK inhibitor SCH 727965, SCH 727965CDK1, 2, 5, 9 inhibitorClinical Trials
VeliparibABT-888PARP inhibitorClinical Trials
NCT02269293IAdvanced ovarian cancer at first recurrenceA Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial CancersNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
SelinexorKPT-330, CRM1 nuclear export inhibitor KPT-330, selective inhibitor of nuclear export KPT-330Selective inhibition of nuclear export (SINE)Approved in Other Cancers
NCT02627443IPlatinum sensitive ovarian cancer at first or second recurrencePhase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerAZ, CO, FL, KY, MI, MN, NJ, PA, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BerzosertibATR kinase inhibitor VX-970, VE-822, M6620, VX-970ATR kinase inhibitorClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NCT02433626IRecurrent ovarian cancerA Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
COTI-2mutant p53 activator COTI-2Mutant p53 activatorClinical Trials
NCT01376505IAdvanced solid tumors (in ovarian expansion)Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccineB-VaxxImmune response against cancer expressing HER2Clinical Trials
NCT02791334IAdvanced solid tumors (in expansion)A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LodapolimabLY3300054Blocks PD-L1 inhibition of T cellsClinical Trials
LY3321367anti-TIM3 monoclonal antibody LY3321367Blocks TIM-3 inhibition of T cellsClinical Trials
Ramucirumabanti-VEGFR-2 fully human monoclonal antibody IMC-1121B, IMC-1121B, LY3009806VEGFR2 antagonistApproved in Other Cancers
NCT02897375IAdvanced solid tumorsA Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid MalignanciesGAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT02498912IMUC16ecto+ recurrent high grade serous ovarian cancer (> 2 prior therapies)A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytesautologous MUC16ecto-targeting EGFR-secreting T lymphocytes, 4H11-28z/fIL-12/EFGRt+ genetically-modified T cellsImmune response against cancer expressing MUC16ectoClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT03017131IRecurrent or refractory ovarian cancerA Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian CancerNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
Decitabinedezocitidine, deoxyazacytidine, 5-aza-dCyd, DacogenDNA methylation inhibitorApproved in Other Cancers
Genetically Engineered NY-ESO-1-specific T LymphocytesImmune response against cancer expressing NY-ESO-1Clinical Trials
NCT03030378IAdvanced solid tumorsA Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid TumorsCA, CO, CT, FL, MD, MA, OH, PA, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IL-12Edodekin alfa, cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12IL-12 receptor agonist
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02972034IAdvanced solid tumorsA Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced MalignanciesMI, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MK-8353ERK1 inhibitor MK-8353ERK inhibitorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02611024IAdvanced solid tumors (inc expansion)Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
LurbinectedinPM01183DNA damaging agentClinical Trials
NCT03056833IPlatinum sensitive recurrent ovarian cancerPhase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03023319IAdvanced solid tumorsPhase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsGAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BosutinibBosulif, SKI-606Abl and src family kinase inhibitorApproved in Other Cancers
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
NCT03069469IAdvanced solid tumors (in expansion)Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced TumorsCA, CO, FL, NY, OR, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DCC-3014CSF1R kinase inhibitorClinical Trials
NCT03054298IRecurrent or persistent mesothelin+ serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
Hu-CART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03154281IAdvanced ovarian cancer (no prior PARPi)A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast CancerSDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EverolimusAfinitor, Certican, RAD001, ZortressmTOR inhibitorApproved in Other Cancers
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT03310541IAdvanced solid tumors with AKT1, AKT2, or AKT3 mutationsA Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3NJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapivasertibAkt inhibitor AZD5363, AZD5363pan-AKT inhibitorClinical Trials
NCT03313778IAdvanced solid tumors with high MSI or high TMB (in expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid TumorsAZ, FL, MA, NJ, NY, NC, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
mRNA-4157mRNA-based personalized cancer vaccine mRNA-4157Immune response against tumor-associated antigensClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03229278IAdvanced solid tumors with high MSIA Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesNJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TrigriluzoleBHV-4157, FC-4157Glutamate antagonistClinical Trials
NCT04149145IRecurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion)Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian CancerALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
M4344VX-803ATR kinase inhibitorClinical Trials
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT04130542IAdvanced solid tumors (inc expansion)An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic MalignancyTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LVGN6051Stimulates 4-1BB (CD137) to increase T cells and immune response
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04134312IAdvanced solid tumorsA Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced CancerMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MVA-BN-brachyurybrachyury-expressing modified vaccinia Ankara-TRICOM vaccineImmune response against cancer expressing brachyuryClinical Trials
NCT04087018IAdvanced solid tumors with high TMB or positive Strata Immune SignatureA Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid TumorsAL, CA, DE, KY, LA, MD, MN, OH, PA, SC, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AB122anti-PD-1 monoclonal antibody AB122Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT04088786IPatients with peritoneal disease who are candidates for grossly complete cytoreduction surgeryPhase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface MalignanciesCA, KY, NYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal irinotecanOnivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecanTopoisomerase I inhibitor
NCT04092270IRecurrent ovarian cancer (inc expansion)A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Ovarian Cancer With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)Contact NCIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitorApproved in Other Cancers
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
NCT04095273IAdvanced solid tumors DNA Damage Repair pathway alterations (inc ovarian expansion)A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid TumorsCA, CT, MD, OH, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BAY1895344ATR kinase inhibitor BAY1895344ATR kinase inhibitorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04007744IAdvanced solid tumors with high MSIA Phase 1 Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsAZ, FL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SonidegibLDE225, Smoothened Antagonist LDE225, Erismodegib, OdomzoSmoothened antagonistApproved in Other Cancers
NCT04034238IAdvanced mesothelin+ solid tumorsA Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LMB-100anti-mesothelin recombinant cytolytic fusion protein RO6927005, anti-mesothelin cytolytic fusion protein LMB-100ADC: anti-mesothelin + Pseudomonas exotoxin (PE)Clinical Trials
TofacitinibTasocitinib, CP-690550JAK kinase inhibitorApproved in Other Indications
NCT04053673IAdvanced solid tumors (inc expansion)A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsCO, FL, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RBN-2397PARP7 inhibitorClinical Trials
NCT03416335IAdvanced solid tumorsA First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsIN, NC, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DSP-0509toll-like receptor 7 agonist DSP-0509TLR7 agonist and immune cell activatorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03968406IRecurrent ovarian cancer (amenable to radiation therapy) - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyRadiotherapy, Irradiation
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitorApproved in Other Cancers
NCT03970382IAdvanced solid tumors (inc expansion)A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid TumorsCAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NeoTCR-P1gene-edited autologous neoantigen-targeted NeoTCR-P1 T cellsImmune response against tumor-associated antigensClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03219268IAdvanced solid tumors, including HER2+ cohort (in ovarian expansion)A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic NeoplasmsAZ, CA, FL, IL, MD, MA, NC, OH, OK, PA, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Margetuximabanti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibodyHER2 antagonist
MGD013dual-affinity retargeting protein MGD013, anti-PD-1/anti-LAG-3 DART protein MGD013Blocks LAG-3 and PD-1 inhibition of T cellsClinical Trials
NCT03363893IAdvanced solid tumors (inc expansion)A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced MalignanciesNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CT7001CDK7 inhibitor CT7001CDK7 inihibitorClinical Trials
NCT03841110IAdvanced solid tumors (inc expansion)FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)CA, MN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
FT500Anti-tumor immune responseClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03849469IAdvanced solid tumors (inc expansion)A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)CA, GA, MA, MI, MO, NY, PA, TX, UTView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
XmAb22841anti-CTLA-4/LAG-3 bispecific antibody XmAb22841Blocks LAG-3 and CTLA-4 inhibition of T cellsClinical Trials
NCT03861793IAdvanced solid tumors (inc expansion)A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)DC, GA, MI, NY, NC, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ALKS 4230intermediate-affinity interleukin-2 receptor agonist ALKS 4230IL-2 receptor agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03556228IAdvanced solid tumors (inc expansion)An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or LymphomaCA, NJ, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VMD-928TrkA inhibitor VMD-928TRK kinase inhibitorClinical Trials
NCT03831295IAdvanced solid tumors - intratumoral injectionIntratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]CAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BMS-986178anti-OX40 antibody BMS 986178Stimulates OX40 to increase T cell activation and immune responseClinical Trials
SD-101TLR9 agonist SD-101, ISS-ODN SD-101TLR9 agonist and immune cell activatorClinical Trials
NCT03748186IRecurrent ovarian cancer (inc expansion)A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer and Endometrial CancersCO, FL, IL, NV, NC, OH, PA, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
STRO-002ADC: anti-FOLR1 + microtubule destabilizer (SC209)Clinical Trials
NCT03139370I